Skip to main content

Citi Investments starts conference call series


NEW YORK Citi Investment Research has begun a Food & Drug conference call series. The first conference call was held on Oct. 8th and was titled, “The Outlook for Specialty Pharmacy and Who Should Benefit.”

Charles Boorady, a managed care analyst for Citi, led most of the discussion which described the growth of specialty drugs, i.e., injectable drugs such as biologics and how the growth of these drugs will benefit pharmacy benefit managers, drug retailers and drug distributors.

Some of the companies Citi expects to see huge results from the increase in specialty drugs are CVS, Express Scripts and Medco Health Solutions. According to Citi, “These firms have the broadest capabilities, the scale to drive efficiencies and lower costs, and the momentum to gain market share.” The company also expects to see the specialty market to increase from $62 billion in 2006 to $1.7 trillion by 2030.

This ad will auto-close in 10 seconds